Ultragenyx Pharmaceutical Inc. (RARE) Leerink Global Healthcare Conference 2026 March 11, 2026 10:00 AM EDT
Company Participants
Eric Crombez – Chief Medical Officer & Executive VP
Conference Call Participants
Joseph Schwartz – Leerink Partners LLC, Research Division
Presentation
Joseph Schwartz
Leerink Partners LLC, Research Division
Good morning, everyone. I’m Joe Schwartz from the biopharma equity research team at Leerink Partners. It’s my pleasure to host our chat with Ultragenyx. We have Eric Crombez , CMO of the company with us today. Thanks so much for joining us.
Eric Crombez
Chief Medical Officer & Executive VP
Great, and thanks for having me.
Joseph Schwartz
Leerink Partners LLC, Research Division
So maybe you can start us off with a brief overview of the company’s recent events and your priorities for this year.
Question-and-Answer Session
Eric Crombez
Chief Medical Officer & Executive VP
Sure thing. I’ll start with our commercial success we’ve had led by Crysvita. So certainly, a lot of continued growth there. Great to see double-digit growth year-over-year, along with Crysvita seeing really great growth with Dojolvi and Evkeeza specifically and also having Mepsevii there in the background. So great background of commercial revenue there supporting everything we’re doing on the pipeline.
And then turning to the pipeline, obviously, a big focus on Angelman with the data readout in the second half of this year, but also really nice to see progress with our gene therapy pipeline. We’ve been working on this for quite a long time. And with our PDUFA date now in hand for GSDIa, getting Sanfilippo closely done behind that, and then obviously, not forgetting about OTC and Wilson there, a lot of depth in that clinical pipeline. And then again, with that maturity and getting these things across the finish line, launching into the commercial space, looking forward to the potential of bringing new things into the pipeline.
